226 related articles for article (PubMed ID: 33121826)
1. Reply to Ethan B. Ludmir, Zachary R. McCaw, and Lee-Jen Wei's Letter to the Editor re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.032. Interpreting the Effect of Ipilimumab following Radiotherapy for Patients with Postdocetaxel Metastatic Castration-resistant Prostate Cancer.
McHenry MB; Drake CG; Fizazi K
Eur Urol; 2021 Jan; 79(1):e12-e13. PubMed ID: 33121826
[No Abstract] [Full Text] [Related]
2. Re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.032: Interpreting the Effect of Ipilimumab Following Radiotherapy for Patients with Postdocetaxel Metastatic Castration-resistant Prostate Cancer.
Ludmir EB; McCaw ZR; Wei LJ
Eur Urol; 2021 Jan; 79(1):e10-e11. PubMed ID: 33109378
[No Abstract] [Full Text] [Related]
3. Reply to Giandomenico Roviello, Alberto Bottini, and Daniele Generali's Letter to the Editor re: Karim Fizazi, Kim N. Chi, Johann S. de Bono, et al. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.02.035. Corticosteroid-associated Adverse Events in Elderly Patients.
Fizazi K; De Porre P; Londhe A; McGowan T; Ryan CJ
Eur Urol; 2016 Aug; 70(2):e42. PubMed ID: 27209539
[No Abstract] [Full Text] [Related]
4. Re: Karim Fizazi, Kim N. Chi, Johann S. de Bono, et al. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.02.035: Corticosteroid-associated Adverse Events in Elderly Patients.
Roviello G; Bottini A; Generali D
Eur Urol; 2016 Aug; 70(2):e41. PubMed ID: 27181830
[No Abstract] [Full Text] [Related]
5. Reply to Robert J. van Soest and Ronald de Wit's Letter to the Editor re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033.
de Bono J
Eur Urol; 2017 Jan; 71(1):e11. PubMed ID: 27751730
[No Abstract] [Full Text] [Related]
6. Reply to Giandomenico Roviello, Daniele Generali, and Roberto Petrioli's Letter to the Editor re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033.
de Bono JS
Eur Urol; 2017 Feb; 71(2):e56. PubMed ID: 27544577
[No Abstract] [Full Text] [Related]
7. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors.
Fizazi K; Drake CG; Beer TM; Kwon ED; Scher HI; Gerritsen WR; Bossi A; den Eertwegh AJMV; Krainer M; Houede N; Santos R; Mahammedi H; Ng S; Danielli R; Franke FA; Sundar S; Agarwal N; Bergman AM; Ciuleanu TE; Korbenfeld E; Sengeløv L; Hansen S; McHenry MB; Chen A; Logothetis C;
Eur Urol; 2020 Dec; 78(6):822-830. PubMed ID: 32811715
[TBL] [Abstract][Full Text] [Related]
8. Re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.010.
Qi F; Xu Z; Zou Q
Eur Urol; 2023 Mar; 83(3):e76-e77. PubMed ID: 36604272
[No Abstract] [Full Text] [Related]
9. Re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033.
van Soest RJ; de Wit R
Eur Urol; 2017 Jan; 71(1):e9-e10. PubMed ID: 27746063
[No Abstract] [Full Text] [Related]
10. Re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033.
Roviello G; Generali D; Petrioli R
Eur Urol; 2017 Feb; 71(2):e55. PubMed ID: 27543166
[No Abstract] [Full Text] [Related]
11. Reply to Vincenza Conteduca, Giorgia Gurioli, and Ugo De Giorgi's Letter to the Editor re: Niven Mehra, David Dolling, Semini Sumanasuriya, et al. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.02.013.
Mehra N; Dolling D; de Bono J
Eur Urol; 2018 Sep; 74(3):e69-e70. PubMed ID: 29866468
[No Abstract] [Full Text] [Related]
12. Reply to Feng Qi, Zicheng Xu, and Qing Zou's Letter to the Editor re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.010.
Loehr A; Chowdhury S; Abida W
Eur Urol; 2023 Mar; 83(3):e78. PubMed ID: 36623951
[No Abstract] [Full Text] [Related]
13. Commentary on: "Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial." Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengeløv L, Hansen S, Logothetis C, Beer TM, McHenry MB, Gagnier P, Liu D, Gerritsen WR, CA184-043 Investigators. Departments of Urology and Immunology and Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, MN, USA, Electronic address: kwon.eugene@mayo.edu; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and Brady Urological Institute, Baltimore, MD, USA; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA; Institut Gustave Roussy, University of Paris-Sud, Villejuif, France; Institut Gustave Roussy, Villejuif, France; VU University Medical Centre, Amsterdam, Netherlands; Vienna General Hospital, Medical University Vienna, Vienna, Austria; Institut Bergonié, Bordeaux, France; CHU Caremeau, Nimes, France; Centro Médico Austral, Buenos Aires, Argentina; Centre Jean Perrin, Clermont-Ferrand, France; St John of God Hospital, Subiaco, WA, Australia; University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy; Hospital de Caridade de Ijuí, Ijuí, Brazil; Nottingham University Hospital, Nottingham, UK; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA; Netherlands Cancer Institute and Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Institute of Oncology Ion Chiricuta and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania; Hospital Británico de Buenos Aires, Buenos Aires, Argentina; Herlev Hospital, Herlev, Denmark; Odense University Hospital, Odense, Denmark; University of Texas MD Anderson Cancer Center, Houston,
Trump D
Urol Oncol; 2016 May; 34(5):249-50. PubMed ID: 25907621
[TBL] [Abstract][Full Text] [Related]
14. Re: Nobuaki Matsubara, Kim N. Chi, Mustafa Özgüroğlu, et al. Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study. Eur Urol. 2020:77:494-500. https://doi.org/10.1016/j.eururo.2019.11.021.
Hess BA
Eur Urol; 2020 Aug; 78(2):e89-e90. PubMed ID: 32291107
[No Abstract] [Full Text] [Related]
15. Reply to Johann S. de Bono, Maha Hussain, and Jinyu Kang's Letter to the Editor re: Konrad H. Stopsack. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.09.024.
Stopsack KH
Eur Urol; 2021 Mar; 79(3):e81-e82. PubMed ID: 33358233
[No Abstract] [Full Text] [Related]
16. Reply to Timothée Olivier, Kerrington Powell, Vinay Prasad. Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.022.
Morris MJ; Sartor O; de Bono JS; Fizazi K; Tagawa ST
Eur Urol; 2023 Jul; 84(1):7-8. PubMed ID: 37032186
[No Abstract] [Full Text] [Related]
17. Reply to Piet R. Dirix, Carole Mercier, and Luc Y. Dirix's Letter to the Editor re: Fabian Lohaus, Klaus Zöphel, Steffen Löck, et al. Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease? Eur Urol 2019;75:548-51.
Hölscher T; Lohaus F; Wirth M; Troost EGC
Eur Urol; 2019 Oct; 76(4):e103-e104. PubMed ID: 31256943
[No Abstract] [Full Text] [Related]
18. Re: Maha Hussain, Joaquin Mateo, Karim Fizazi, et al. Survival with Olaparib in Metastatic Castration-resistant Prostate Cancer. N Engl J Med. In press. https://doi.org/10.1056/NEJMoa2022485.
Rizzo A; Mollica V; Massari F
Eur Urol Oncol; 2020 Dec; 3(6):806. PubMed ID: 33206598
[No Abstract] [Full Text] [Related]
19. Reply to Joe O'Sullivan, Daniel Heinrich, Nicholas D. James, et al.'s Letter to the Editor re: The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer. Eur Urol 2019;75:e51-2.
On Behalf Of Ema
Eur Urol; 2019 Mar; 75(3):e53. PubMed ID: 30658854
[No Abstract] [Full Text] [Related]
20. Re: Konrad H. Stopsack. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.09.024.
de Bono J; Hussain M; Kang J
Eur Urol; 2021 Mar; 79(3):e83-e84. PubMed ID: 33358234
[No Abstract] [Full Text] [Related]
[Next] [New Search]
